Pablo Corral/LinkedIn
Oct 29, 2025, 07:39
Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“Pushing the limits of LDLc: Emerging paradigms in CV risk reduction
- Modern guidelines now target LDL-C <55 mg/dL, and even <40 mg/dL for the highest-risk patients.
- Evidence from FOURIER, ODYSSEY, and IMPROVE-IT confirms that the lower, the better — with no safety concerns, even below 25 mg/dL.
- Genetic data (PCSK9 LoF, APOB, ANGPTL3) reinforce that lifelong low LDL-C protects against ASCVD.
- Emerging therapies — PCSK9 inhibitors, inclisiran, bempedoic acid, ANGPTL3 inhibitors — make these targets achievable.
- Cognitive, endocrine, and hemorrhagic risks remain none at very low LDL-C.
The real challenge is no longer how low can we go, but how many actually get there.”
Stay updated with Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis